[4-(5-aminomethyl-2-fluoro-phenyl)-pipe ridin1-yl]-(4-bromo-3-methyl-5-propoxy-thio phen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase

Details for Australian Patent Application No. 2005230934 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors Davis, Larry; Haddad, El-Bdaoui; Gao, Zhongli; Czekaj, Mark; Sledeski, Adam W.; Levell, Julian

Agent Watermark

Pub. Number AU-A-2005230934

PCT Pub. Number WO2005/097780

Priority 60/556,927 26.03.04 US

Filing date 24 March 2005

Wipo publication date 20 October 2005

International Classifications

C07D 409/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

Event Publications

5 October 2006 PCT application entered the National Phase

  PCT publication WO2005/097780 Priority application(s): WO2005/097780

9 April 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005230936-Base specific cleavage of methylation-specific amplification products in combination with mass analysis

2005230932-Wear edge assembly